Blood coagulation and fibrinolysis in patients with Cushing's syndrome: Increased plasminogen activator inhibitor-I, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels

Journal of Endocrinological Investigation

Volumn 32, Issue 2, 2009, Pages 169-174

  Erem, C ^a   Nuhoglu, I ^a   Yilmaz, M ^b   Kocak, M ^a   Demirel, A ^a   Ucuncu, O ^a   Ersoz, H Onder ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^b Division of Hematology   (Turkey)

Author keywords

Cushing's syndrome; Hemostatis; Thrombin activatable fibrinolysis inhibitor; Tissue factor pathway inhibitor

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; HYDROCORTISONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; CUSHING SYNDROME; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; MALE; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME;

EID: 67649373249     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345709     Document Type: Article

References (46)

1. De Martin M, Pecori Giraldi F, Cavagnini F. Cushing's disease. Pituitary 2006, 9: 279-87.
2. Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf) 2004, 61: 768-77.
3. Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: An epidemiological approach. Gun Endocrinol l0x 1994, 40: 479-84.
4. Baykan M, Erem C, Gedikli O, et al. Impairment of flow-mediated vasodilatation of brachial artery in patients with Gushing's Syndrome. Endocrine 2007, 31: 300-4.
5. Dagenais GB, Yi O, Mann JF, Bosch J, Pogue J, Yusuf S. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J 2005, 149: 54-60.
6. Ambrosi B, Sartorio A, Pizzocaro A, Passini E, Bottasso B, Federici A. Evaluation of haemostatic and fibrinolytic markers in patients with Gushing's syndrome and in patients with adrenal incidentaloma. Exp Gun Endocrinol Diabetes 2000, 108: 294-8.
7. Boscaro M, Sonino N, Scarda A, et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Gushing's syndrome. J Clin Endocrinol Metab 2002, 87: 3662-6.
8. Fatti LM, Bottasso B, Invitti C, Coppola R, Cavagnini F, Mannucci PM. Markers of activation of coagulation and fibrinolysis in patients with Gushing's syndrome. J Endocrinol Invest 2000, 23: 145-50.
9. Patrassi GM, Dal Bo Zanon R, Boscaro M, Martinelli S, Girolami A. Further studies on the hypercoagulable state of patients with Gushing's syndrome. Thromb Haernost 1985, 54: 518-20.
10. Shibli-Rahhal A, Van Beek M, Schlechte JA. Gushing's syndrome. Clin Dermatol 2006, 24: 260-5.
11. Dal Bo Zanon R, Fomasiero L, Boscaro M, et al. Increased factor VIII associated activities in Cushing's syndrome: a probable hypercoagulable state. Thromb Haemost 1982, 47: 116-7.
12. Dal Bo Zanon R, Fornasiero L, Boscaro M, et al. Clotting changes in Gushing's syndrome: elevated factor VIII activity. Folia Haematol Int Meg Kliri Morphol Blutforsch 1983, 110: 268-77.
13. La Brocca A, Terzolo M, Pia A, Paccotti P, De Giuli P, Angeli A. Recurrent thromboembolism as a hallmark of Gushing's syndrome. J Endocrinol Invest 1997, 20: 211-4.
14. Sjöberg HE, Blombäck M, Granberg PO. Thromboembolic complications, heparin treatment in increase in coagulation factors in Gushing's syndrome. Acta Med Scand 1976, 199: 95-8.
15. Yoshimura S, Ago T, Kitasono T, et al. Cerebral sinus thrombosis in a patient with Gushing's syndrome. J Neurol Neurosurg Psychiatry 2005, 76: 1182-3.
16. Jacoby RG, Owings JT, Ortega T, Gosselin R, Feldman EC. Biochemical basis for the hypercoagulable state seen in Gushing syndrome; discussion 1006-7. Arch Surg 2001, 136: 1003-6.
17. Small M, Lowe GD, Forbes GD, Thomson JA. Thromboembolic complications in Gushing's syndrome. Clin Endocrinol 1983, 19: 503-11.
18. Rooth E, Wallen H, Antovic A, et al. Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke. Blood Goagul Fibrinolysis 2007, 18: 365-70.
19. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen aystem. J Gun Invest 1995, 96: 2534-8.
20. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000, 95: 2855-9.
21. Eichinger 5, Schönauer V, Weltermann A, Minar E, Bialonczyk G, Hirschl M, Schneider B, Quehenberger P, Kyrle PA. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004, 103: 3773-6.
22. Leebeek FW, Goor MP, Guimaraes AH, et al. High functional levels of thrombin-activatable fibririolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 2005, 3:2211-8.
23. Montaner J, Ribó M, Monasterio J, Molina CA, Alvarez-Sabín J. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 2003, 34: 1038-40.
24. Ravindranath TM, Goto M, Iqbal O, et al. Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis. Clin AppI Thromb Hemost 2007, 13: 362-8.
25. Broze GJ Jr. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 1992, 29: 159-69.
26. Abumiya T, Yamaguchi T, Terasaki T, Kokawa T, Kario K, Kato H. Decreased plasma tissue factor pathway inhibitor activity in ischemic stroke patients. Thromb Haemost 1995, 74: 1050-4.
27. Kobayashi M, Wade H, Wakita Y, et al. Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1995, 73: 10-4.
28. Harris GM, Stendt GL, Vollenhoven BJ, Gan TE, Tipping PG. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives. Am J Hematol 1999, 60: 175-80.
29. Colao A, Pivonello R, Spiezia S, et al. Persistence of increased cardiovascular risk in patients with Gushing's disease after five years of successful cure. J CIin Endocrinol Metab 1999, 84: 2664-72.
30. Amaldi G, Angeli A, Atkinson AS, et al. Diagnosis and complications of Gushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003, 88: 5593-602.
31. Luksenburg HS, Goldberg SL, Kessler CM. Hematologic Endocrinology. In: Becker KL ed. Principles and Practice of Endocrinology and Metabolism. Third Edition, Lippincott Williams and Wilkins, 2001, pp.1927-37.
32. Girolami A, Simioni P, Scarano L, Girolami B. Venous and arterial thrombophilia. Haematologica 1997, 82: 96-100.
33. Patrassi GM, Sartori MT, Viero ML, Scarano L, Boscaro M, Girolami A. The fibrinolytic potential in patients with Gushing's disease: A clue to their hypercoagulable State. Blood Coagul Fibrinolysis 1992, 3: 789-93.
34. Meade TW, Mellows 5, Brozovic M, et al. Haemostatic function and ischaemnic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986,2:533-7.
35. Feinbloom D, Bauer KA. Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vasc Biol 2005, 25: 2043-53.
36. Quinsey NS, Greedy AL, Bottomley SP, Whisstock JC, Pike RN. Antithrombin: In control of coagulation. lnt J Biochem Cell Biol 2004, 36: 386-9.
37. Roemisch J, Gray E, Hoffmann JN, Wiedermann CJ. Antithrombin: A new look at the actions of a serine protease inhibitor. Blood Coagul Fibrinolysis 2002, 13: 657-70.
38. Bayston TA, Lane DA. Antithrombin: molecular basis of deficiency. Thromb Haemost 1997, 78: 339-43.
39. Feldman BF, Rasedee A, Feldman EC. Haemostatic abnormalities in canine Cushing's syndrome. Res Vet Sci 1986, 41: 228-30.
40. Moss AJ, Goldstein RE, Marder VJ, et al. Thrombogenic factors and recurrent coronary events. Circulation 1999, 99: 2517-22.
41. Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol 2006, 208: 327-39.
42. Hoke M, Kyrle PA, Minar E, et al. Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism. Thromb Haemost 2005, 94: 787-90.
43. Monasterio J, Bermúidez P, Quiroga D, Francisco E, Meneses B, Montaner J. Plasma thrombin-activatable fibrinolytic inhibitor (TAFI) among healthy subjects and patients with vascular diseases: a validation study. Pathophysiol Haemost Thromb 2003-2004, 33: 382-6.
44. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995, 270: 14477-84.
45. Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000, 95: 2855-9.
46. Juhan-Vague I, Morange PE, Aubert H, et al; HIFMECH Study Group. Plasma thrornbin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to rnyocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 2002, 22: 867-73.